^
Association details:
| Biomarker: | EGFR exon 19 deletion |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | patritumab deruxtecan (U3-1402) (Topoisomerase I inhibitor, HER3-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Patritumab Deruxtecan in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer
Excerpt:
...- Documentation of EGFR exon 19 deletion or L858R mutation detected from tumor tissue...
Source:
Title:
Medical Access Program for Patritumab Deruxtecan
Excerpt:
...- Histologically or cytologically documented locally advanced or metastatic EGFRm NSCLC...
Trial ID:
More C2 evidence
Source:
Title:
U3-1402 in Metastatic or Unresectable Non-Small Cell Lung Cancer
Excerpt:
...Has acquired resistance to EGFR TKI according to the Jackman criteria (...
Trial ID:
Source:
Title:
Patritumab Deruxtecan in Subjects with Metastatic or Locally Advanced EGFR-mutated NSCLC
Excerpt:
...Subjects must have received both of the following: a. ≥1 prior line(s) of EGFR TKI treatment (erlotinib, gefitinib, afatinib, dacomitinib or simertinib). ...
Trial ID:
Source:
Title:
HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer
Excerpt:
...Participants receiving an EGFR TKI at the time of signing informed consent should continue to take the EGFR TKI until 5 days prior to Cycle 1 Day 1....
Trial ID:
Less C2 evidence
Source:
Title:
HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor–Mutated Non–Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy
Published date:
09/10/2023
Excerpt:
HERTHENA-Lung01 (ClinicalTrials.gov identifier: NCT04619004) is a multicenter, open-label, randomized, two-arm, phase II study of HER3-DXd once every 3 weeks in previously treated patients with locally advanced or metastatic NSCLC with EGFR-activating mutations (exon 19 deletion or L858R) being conducted in 122 location...HER3-DXd once every 3 weeks demonstrated clinically meaningful efficacy, including durable intracranial responses, with a manageable safety profile in patients with previously treated EGFR-mutated NSCLC.
DOI:
10.1200/JCO.23.01476
Trial ID:
Source:
Title:
Safety and preliminary antitumor activity of U3-1402: A HER3-targeted antibody drug conjugate in EGFR TKI-resistant, EGFRm NSCLC.
Excerpt:
...U3-1402 safety/tolerability and preliminary activity in metastatic or unresectable EGFRm NSCLC patients...10 pts had EGFR exon 19 deletion and 5 EGFR L858R mutation....U3-1402 showed a manageable safety profile and preliminary antitumor activity in EGFR TKI-resistant EGFRm NSCLC.
DOI:
10.1200/JCO.2019.37.15_suppl.9010
Trial ID:
